Phathom Pharmaceuticals, Inc. (PHAT)
Develops heartburn and stomach ulcer treatments for patients with acid reflux diseases.
$11.66-0.02%Healthcare
StockGlow Score
Leaning Bullish
BearishBullish
1 year ago+39.6%
The outlook
PHAT is trading near the lower end of its 52-week range, with analyst consensus strongly bullish and an average price target roughly double the current price. The stock shows mixed momentum against its moving averages, suggesting choppy near-term price action despite the constructive analyst view.
What’s behind the score
Analyst consensusStrong Buy — 1.4 avg of 10 analysts
Price trendMixed vs its moving averages
52-week range35% of the way from its 52-week low to high
Price targetAvg target +103% vs current price
Analyst price target
~12-month · 10 analysts$23.70average target+103.3% vs now
Now $11.66
Low $13.00High $29.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$930.0M
52-wk high
$18.31
52-wk low
$8.03
50-day avg
$10.93
200-day avg
$12.69
Trailing P/E
—